← Back
Data updated: Mar 10, 2026
IDORSIA
CardiovascularGastroenterologyNeurology
IDORSIA is a pharmaceutical company focused on Cardiovascular, Gastroenterology, Neurology. Key products include QUVIVIQ.
2022
Since
2
Drugs
-
Trials
7
Approved (2yr)
Key Drugs
Recent Activity
TRYVIO 2025-04-02
REMS
TRYVIO 2024-12-09
REMS
QUVIVIQ 2024-09-30
Efficacy
QUVIVIQ 2024-09-30
Labeling
QUVIVIQ 2024-09-30
Efficacy
TRYVIO 2024-08-07
REMS
TRYVIO 2024-03-19
Type 1 - New Molecular Entity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 76%
1 drugs Phase 3: 2 Phase 2: 1
Gastroenterology 10%
0 drugs Phase 1: 2
Neurology 10%
0 drugs Phase 2: 1
Respiratory 5%
0 drugs Phase 1: 1
Pipeline Strength Pro
Loading...
Competitors Pro
GE HEALTHCARE specialty
Neurology, Cardiovascular, Respiratory
APOTHECON specialty
Cardiovascular, Gastroenterology, Respiratory
LEDERLE big-pharma
Cardiovascular, Neurology, Respiratory
Novartis big-pharma
Cardiovascular, Respiratory
VALIDUS PHARMS specialty
Cardiovascular, Gastroenterology, Neurology